CGRP Education & Research Forum
Already a member? Become a member Register
youtubeLinkedIn
Latest:

What advice would you give clinicians about how patients can obtain reimbursement for anti-CGRP therapies?

Professor Fernando Kowacs proposes the type of medical report that is needed to achieve a successful initial application for reimbursement of CGRP monoclonal antibodies for a patient, and how this can be updated for continuing reimbursement success.  

Read more »

Que conselhos daria aos médicos para ajudar os pacientes a obter o reembolso de terapias anti-CGRP?

O Professor Kowacs propõe o tipo de relatório médico a ser usado para que os pacientes recebam o reembolso de tratamento com anticorpos monoclonais CGRP e como deve ser feita a atualização do relatório.  

Read more »

O que os médicos devem saber sobre a combinação de terapias anti-CGRP com outros tratamentos para a migrânea?

Com o aumento do uso dos anticorpos monoclonais CGRP em combinação com outras terapias preventivas, como a onabotulinumtoxinaA, o Professor Kowacs discute as oportunidades para quem sofre de migrânea difícil de tratar.  

Read more »

What should clinicians know about combining anti-CGRP therapies with other migraine treatments?

As CGRP monoclonal antibodies are increasingly used in combination with other preventive therapies, such as onabotulinumtoxinA, Professor Fernando Kowacs discusses the opportunities for patients with the hardest to treat migraine.  

Read more »

Quais pacientes podem se beneficiar das terapias anti-CGRP e como é o acompanhamento de terapias anti-CGRP?

O Professor Fernando Kowacs considera quais pacientes podem se beneficiar dos anticorpos monoclonais CGRP e descreve os fatores que influenciam sua escolha de medicamento para cada paciente, a abordagem de acompanhamento e as estratégias de troca para quem não responde bem a eles.  

Read more »

Which patients in Brazil are suitable for anti-CGRP therapies and how do you follow up people on anti-CGRP therapies?

Professor Fernando Kowacs considers which patients may benefit from CGRP monoclonal antibodies and describes the factors that influence his choice of drug for individual patients as well as his approach to follow up, and his switching strategies for poor responders.  

Read more »

Quão boas são as evidências apoiando as terapias anti-CGRP?

Há cada vez mais evidências que apoiam a eficácia, a segurança e a tolerabilidade dos anticorpos monoclonais CGRP. O Professor Fernando Kowacs revisa alguns dos principais achados de ensaios clínicos e relata evidências do mundo real publicadas por médicos no Brasil.   

Read more »

Quais são os principais problemas enfrentados pelos médicos que tratam a migrânea no Brasil?

O Professor Fernando Kowacs explica que alguns pacientes esperam anos pelo diagnóstico correto e enfatiza a necessidade de maior disponibilidade de terapias eficazes preventivas e agudas de migrânea, incluindo anticorpos monoclonais CGRP.   

Read more »

Quão comum é a migrânea no Brasil e como ela é tratada

Uma em cada cinco mulheres e um em cada 10 homens sofrem de migrânea no Brasil, com níveis significativos de incapacidade. O Professor Fernando Kowacs discute a prevalência de migrânea no Brasil e os tipos de tratamento disponíveis.   

Read more »

How good is the evidence supporting anti-CGRP therapies?

A growing body of evidence supports the efficacy, safety and tolerability of CGRP monoclonal antibodies. Professor Fernando Kowacs reviews some of the key clinical trial findings and reports real world evidence published by clinicians in Brazil.  

Read more »

What are the main problems for doctors treating migraine in Brazil?

Professor Fernando Kowacs explains that some patients wait years before they are correctly diagnosed with migraine, and stresses the need for wider availability of effective preventive and acute migraine therapies, including CGRP monoclonal antibodies.  

Read more »

How common is migraine in Brazil and how is it treated?

Approximately one in five women and one in 10 men suffer from migraine in Brazil, with significant levels of disability. Professor Fernando Kowacs discusses the prevalence of migraine in Brazil and the types of treatment available for patients.  

Read more »

Combining CGRP mAbs and gepants: what do we know?

As CGRP monoclonal antibodies (mAbs) are rarely 100% effective at preventing migraine, clinicians are starting to combine them with gepants to treat breakthrough headaches. Richard Lipton, Edwin S Lowe Professor of Neurology at the Albert Einstein College of Medicine, New York, USA, explains that there is a growing body of evidence from pharmacokinetic and observational …

Read more »

2020 brought new hope for patients with migraine – how will 2021 build on this success?

For Patricia Pozo-Rosich, 2020 was an important year for patients with migraine, especially in Spain where she works. With access to anti-CGRP therapies becoming available for the first time, neurologists were able to educate their patients about the new agents and start to see the effects in clinical practice. Clinical trial data published in 2020 …

Read more »

Anti-CGRP therapies – what did we learn in 2020 and what can we expect in 2021?

2020 was another momentous year for anti-CGRP therapies.  With the last of the CGRP monoclonal antibodies and the first gepants gaining their first approvals in the USA,1-3 and other anti-CGRP therapies gaining approvals around the world, clinicians have seen a rapid increase in the range of treatments available for their patients with migraine. New clinical …

Read more »

Migraine: a new treatment landscape

As clinicians witness a revolution in thinking about migraine and its treatment, Peter Goadsby considers how the future availability of CGRP monoclonal antibodies and small molecule gepants will change the treatment landscape. He welcomes the growing opportunities for patients to be offered individualised treatment that enables them to take back control of their lives.  

Read more »

CGRP in cluster headache

In the third in his series of videos about the future of CGRP therapies, Peter Goadsby describes the research that led to the approval of galcanezumab for the treatment of episodic cluster headache and looks forward to better understanding of how treatment can be optimised for patients most likely to benefit.

Read more »

CGRP therapies in acute migraine

Following the US approval of the first CGRP small molecule receptor antagonist, ubrogepant, for the acute treatment of migraine, Peter Goadsby looks at the potential impact of targeting the CGRP pathway for both prevention and treatment of migraine.

Read more »

What next for anti-CGRP therapy?

Extensive clinical trial data support the efficacy and safety of anti-CGRP therapies in patients with migraine but there is still much to be learned about their precise role in daily practice. In the first of a series of videos about what comes next for anti-CGRP therapy, Peter Goadsby discusses the challenges that still need to …

Read more »

Become a member of CGRP Forum

The Calcitonin Gene-Related Peptide (CGRP) Forum has been established by an international group of clinicians and researchers. It provides all healthcare professionals with open and free access to independent news, information, comment and resources about the exciting potential of CGRP as a novel therapeutic target for the prevention of migraine in millions of people worldwide.

Read more »

Why is CGRP an important therapeutic target?

Multiple lines of evidence support a role for CGRP in migraine pathophysiology. Its blockade is now a potentially important therapeutic target for migraine prevention.

Read more »